Andrzej Gackowski

Prof. Andrzej Gackowski

Department of Coronary Artery Disease and Heart Failure, Jagiellonian University Medical College, John Paul II Hospital, Kraków, Poland

Research Focus & Metrics

Academic Career Length

33Years (1994-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 October 2004 in European Heart Journal
Verified
Journal Article
Closed access
AGAndrzej Gackowski
Andrzej Gackowski
RIR Isnard
R Isnard
JGJ Golmard
J Golmard
FPF Pousset
F Pousset
ACA Carayon
A Carayon
MKM Komajda
M Komajda
Comparison of the value of echocardiography and B-type natriuretic peptide (BNP) in monitoring response to treatment in patients admitted for acute heart failure (HF). Ninety-five consecutive patients admitted with acute HF underwent bedside Doppler echocardiography and BNP measurements on admission, after 24 h of intravenous treatment, and at day 7. We then studied the association between the clinical status, the Doppler echocardiographic findings, the BNP measurements and subsequent 60-day adverse outcome (death, resuscitated cardiac arrest, urgent heart transplantation, readmission). On admission and during hospitalisation, relationships were found between plasma BNP and Doppler echocardiographic findings, and between their changes. During a 60 day follow-up, 37 events occurred. Multivariable analysis taking into account clinical factors, Doppler echocardiography and BNP showed that the two best models to predict outcome were (1) early evaluation at day 2 (previous CHF treatment, dobutamine use, relative BNP change during first 24 h) and (2) late evaluation at day 7 (previous CHF treatment, dobutamine use, BNP at day 7). Patients with a decrease in plasma BNP >10% at day 2, or with plasma BNP <300 pg/ml at day 7 had a better outcome than the others (19% versus 65% and 16% versus 72% events, respectively, p<0.0001). Serial BNP measurements during the treatment of acute HF provide incremental prognostic information over clinical presentation and repetitive echocardiographic examination.

1 January 2018 in JACC
Verified
Journal Article
Closed access
JGJames S. Gammie
James S. Gammie
KBKrzysztof Bartus
Krzysztof Bartus
AGAndrzej Gackowski
Andrzej Gackowski
MDMichael N. D’aMbra
Michael N. D’aMbra
PSPiotr Szymanski
Piotr Szymanski
PKPiotr Kolsut
Piotr Kolsut

19 July 2016 in Circulation
Verified
Journal Article
Open access
PDF file
JGJames S. Gammie
James S. Gammie
PWPeter Wilson
Peter Wilson
KBKrzysztof Bartus
Krzysztof Bartus
AGAndrzej Gackowski
Andrzej Gackowski
JHJudy Hung
Judy Hung
MGMehrdad Ghoreishi
Mehrdad Ghoreishi
Background: Degenerative mitral valve (MV) disease is a common cause of severe mitral regurgitation (MR) and accounts for the majority of MV operations. Conventional MV surgery requires cardiopulmonary bypass, aortic cross-clamping, cardioplegia, and a thoracotomy or sternotomy and, therefore, is associated with significant disability, risks, and unpredictable rates of MV repair. Transesophageal echocardiography–guided beating-heart MV repair with expanded polytetrafluoroethylene cordal insertion has the potential to significantly reduce surgical morbidity. We report the first-in-human clinical experience with a novel preformed expanded polytetrafluoroethylene knot implantation device (Harpoon TSD-5) designed to treat degenerative MR. Methods: Through a small left thoracotomy, the device was inserted into the heart and guided by transesophageal echocardiography to the ventricular surface of the prolapsed leaflet. Multiple expanded polytetrafluoroethylene cords were anchored in the leaflet and then adjusted to the correct length to restore MV leaflet coaptation and secured at the epicardium. Results: Eleven patients with posterior leaflet prolapse and severe MR, with mean±SD age of 65±13 years and mean ejection fraction of 69±7%, were treated with 100% procedural success. Immediate postprocedural mean MR grade was trace. At 1 month, the mean MR grade was mild with significant decreases in end-diastolic volume (139 to 107 mL; P =0.03) and left atrial volume (118 to 85 mL; P =0.04). Conclusions: A novel device used for beating-heart image-guided MV repair demonstrates a significant reduction in MR with favorable left ventricular and left atrial reverse remodeling. This approach has the potential to decrease invasiveness and surgical morbidity. Further follow-up is necessary to assess long-term efficacy. Clinical Trial Registration: URL: https://clinicaltrials.gov . Unique identifier: NCT02432196.

31 August 2007 in European Heart Journal
Verified
Journal Article
Open access
PDF file
EKEwa Konduracka
Ewa Konduracka
AGAndrzej Gackowski
Andrzej Gackowski
PRPawel Rostoff
Pawel Rostoff
DGDanuta Galicka-Latala
Danuta Galicka-Latala
WFWieslaw Frasik
Wieslaw Frasik
WPWieslawa Piwowarska
Wieslawa Piwowarska
The incidence of diabetic cardiomyopathy, independent of arterial hypertension (AH) and coronary heart disease (CHD), remains controversial. The present study aimed to determine the influence of type 1 diabetes mellitus (T1DM) of long duration (>10 years) on myocardial function estimated by echocardiography (ECHO) and serum level of N-terminal pro-B type natriuretic peptide (NT-proBNP) in patients without CHD and AH. We also retrospectively investigated the relationship between the structural changes in the hearts of other deceased T1DM patients, and had their myocardial function echocardiographically assessed before death. In 185 patients (96 males) with T1DM (mean duration 22.8 years) and 105 non-diabetic control subjects (57 males), detailed ECHO parameters and NT-proBNP were assessed. No significant differences were found between the respective groups. Histological studies of 17 hearts of deceased T1DM patients were carried out and retrospectively compared with their ECHO performed before death. Histological changes were identified, although without the signs of myocardial dysfunction on ECHO prior to death. Even the application of echocardiographic, biochemical and morphologic techniques hardly gives sufficient grounds to believe that type 1 diabetes alone may actually precipitate myocardial dysfunction, despite long-term course of the disease and typical histological changes in the myocardium.

3 May 2010 in European Heart Journal
Verified
Journal Article
Open access
PDF file
EGEstelle Gandjbakhch
Estelle Gandjbakhch
AGAndrzej Gackowski
Andrzej Gackowski
SMSophie Tezenas du Montcel
Sophie Tezenas du Montcel
RIRichard Isnard
Richard Isnard
AHAmel Hamroun
Amel Hamroun
PCPhilippe Charron
Philippe Charron
Preliminary studies suggested that tissue Doppler imaging (TDI) was able to identify mutation carriers in familial hypertrophic cardiomyopathy (HCM) before the development of hypertrophy. However, data are limited. We performed a systematic analysis of echocardiography, TDI, and electrocardiogram (ECG) in familial HCM to identify parameters associated with genetic status. We analysed 120 adults spread out in three groups: HCM patients with hypertrophy (LVH+, n = 48), mutation carriers without hypertrophy (LVH−/G+, n = 24), and normal control subjects (n = 48). Several parameters were significantly different in LVH−/G+ compared with controls. Multivariate logistic regression identified only three independent echographic/TDI parameters associated with genetic status: the inter-ventricular septum/left posterior wall ratio (P = 0.006), relative wall thickness (P = 0.026), and septal E/Ea ratio (P = 0.008). An echo/TDI score determined after receiver operating characteristic analysis identified mutation carriers with 67% sensitivity and 96% specificity. In comparison, only 29% were identified by the previously proposed TDI criterion (lateral Ea velocity <14 cm/s) and only 33% by major ECG abnormalities. Tissue Doppler imaging velocities alone were not reliable enough to identify LVH-free mutation carriers in HCM. In contrast, abnormal LV remodelling was a frequent early manifestation of HCM. We developed a new score, combining echocardiographic and TDI parameters, that identifies mutation carriers before and independently of hypertrophy with high accuracy.

1 October 2010 in International Journal of Cardiology
Verified
Journal Article
Closed access
PRPawel Rostoff
Pawel Rostoff
GGGrzegorz Gajos
Grzegorz Gajos
EKEwa Konduracka
Ewa Konduracka
AGAndrzej Gackowski
Andrzej Gackowski
JNJadwiga Nessler
Jadwiga Nessler
WPWieslawa Piwowarska
Wieslawa Piwowarska